3Nussler V,Pelka--Fleischer R, Zwierzina H et al. P--glycoprotein expression in patients with acute leukemia clinical relevance [J]. Leukemia, 1996, 10(Suppl 3) :523-531.
4Ludescher C,Eisterer W, Hibes W et al. Low frequency of activity of P -- glycoprotein (P -- gp ) in acute lymphoblastic leukemia compared to acute myeloid leukemia [J]. Leukemia, 1995,9 : 350-356.
5Krause DS, Fackler MJ, Civin CI et al. CD34 : structure, biology and clinical utility[J]. Blood, 1996,87: 1-13.
6Campos L,Guyotat D,Archimband B et al. Clinical significance of multidrug resistance P--glycoproyein expression on acute nonlymphoblastic leukemia cells at diagnosis [J]. Blood, 1992,79: 473.
7Goasguen JE,Dossot JM,Fardel O et al. Expression of the multidrug resistance-associated P-glycoprotein (P170) in 59 cases of de novo acute lymphoblastic leukemia : Prognostic implication [J]. Blood, 1993,81 :2394-2398.
8Campos L, Guyotat D, Archimbaud E et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis[J]. Blood, 1992,79:473-476.
9Boekhorst P, Lee KD, Schoester M et al. Predominance of functional multidrug resistance(MDR) phenotype in CD34+ acute myeloid leukemia cells [J].Blood ,1993,82:3157-3162.
10Michieli M, Damiani D, Ermacora A et al. P -- glycoproyein (P--gp) and lung resistance--related protein (LRP) expression and function in leukemic blast cells[J]. Br J Haematol, 1997,96: 356-365.
